32193-12-7

Upstream product

• 29242-28-2 acide α-methyl β-p-chloro-benzoyl lactique 
• 28657-47-8 methyl-4 hydroxy-4 (p-chloro phenyl)-6 pyridazinone-3 
• 845961-27-5 4-(4-Chloro-phenyl)-2-methylene-4-oxo-butyric acid methyl ester 
• 5754-18-7 4-methyl-1,2-dihydropyridazine-3,6-dione 
• 99-91-2 para-chloroacetophenone 
• 910229-66-2 5-methyl-6-oxo-1,6-dihydropyridazin-3-yl 2,4,6-triisopropylbenzenesulfonate 
• 1679-18-1 4-Chlorophenylboronic acid 
• 108-90-7 chlorobenzene 
• 2170-03-8 itaconic acid anhydride 

Downstream Products

• 28657-38-7 3-chloro-6-(4-chloro-phenyl)-4-methyl-pyridazine 
• 109854-56-0 4-methyl-6-p-chlorophenyl-pyridazin-3⁽²⁾-thiones 
• 120317-62-6 6-(4-Chloro-phenyl)-4-methyl-4-phenyl-4,5-dihydro-2H-pyridazine-3-thione 
• 118269-85-5 [6-(4-Chloro-phenyl)-4-methyl-pyridazin-3-yl]-(2-morpholin-4-yl-ethyl)-amine; hydrochloride 

Relevant academic research and scientific papers

Sequential regio and chemoselective cross-coupling reactions by means of O6-tri-isopropylsulfonate of 4-bromo-pyridazine 3,6-dione

Regioselective desymmetrization of 4-substituted pyridazin-3,6-diones using sterically hindered 2,4,6-triisopropylphenyl-sulfonylchloride allowed efficient sequential palladium cross-coupling reactions.

Synthesis and hypotensive activity of some 6-(substituted aryl)-4-methyl-2,3-dihydropyridazin-3-ones

6-(Substituted aryl)-4-methyl-2,3-dihydropyridazin-3-ones are synthesized by cyclisation of appropriate β-(substituted aroyl)-2-methylene propionate with hydrazine hydrate in the presence of sodium acetate. The title compounds are tested for hypotensive activity, non-invasively, by tail-cuff method and are found to possess significant hypotensive activity in normotensive rats.

Endothelin receptor antagonists

This invention relates to pyridizinone derivatives of formula I STR1 wherein the various substituents are defined in the specification, and salts thereof, which have useful pharmacological properties, in particular endothelin receptor-antagonistic properties. The compounds are thus useful for the treatment of illnesses associated with endothelin activities, such as hypertension, cardiac insufficiency, coronary heart disease, renal, cerebral and myocardial ischaemia, renal insufficiency, cerebral infarct, subarachnoid haemorrhage, arteriosclerosis pulmonary high blood pressure, inflammations, asthma, prostate hyperplasia, endotoxic shock and in complications after the administration of immunosuppressants which produce renal vasoconstriction.

3-Aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities

Minaprine [3[(β-morpholinoethyl)amino]4-methyl-6-phenylpyridazine dihydrochloride] is active in most animal models of depression and exhibits in vivo a dual dopaminomimetic and serotoninomimetic activity profile. In an attempt to dissociate these two effe

Obtention selective d'hydroxy-4 pyridazinones-3 et de pyridazones-3. Etude des modalites de la cyclocondensation des acides β-acyl lactiques avec l'hydrazine

The authors reinvestigate the cyclocondensation reaction of β-acyl lactic acids with hydrazine and propose operating conditions allowing a selective and quantitative access either to 4-hydroxypyridazin-3 ones or, directly, to the corresponding pyridazin-3- ones.

Substituted phenyl-1,2,4-triazolo[2,3-b]pyridazin-3(2H)ones as anti-asthma agents

Substituted phenyl-1,2,4-triazolo[4,3-b]pyridazin-3(2H)-ones, useful as anti-asthma agents.

Method for treating anxiety in mammals

This disclosure describes compositions of matter useful as anxiolytic agents and the method of meliorating anxiety in mammals therewith; the active ingredients of said compositions of matter being certain substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines or the pharmacologically acceptable acid-addition salts thereof.

6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents

This disclosure describes novel substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines useful as hypotensive agents.